

John Morser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8797207/publications.pdf>

Version: 2024-02-01

56
papers

2,739
citations

236925

25
h-index

175258

52
g-index

57
all docs

57
docs citations

57
times ranked

2545
citing authors

#	ARTICLE	IF	CITATIONS
1	Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 238-244.	3.8	3
2	Thrombin cleavage of osteopontin initiates osteopontin's tumor-promoting activity. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1256-1270.	3.8	10
3	Chemerin regulates formation and function of brown adipose tissue: Ablation results in increased insulin resistance with high fat challenge and aging. <i>FASEB Journal</i> , 2021, 35, e21687.	0.5	3
4	Role of activation of the coagulation system in the pathogenesis of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3243-3244.	5.7	1
5	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 538-564.	3.4	64
6	Antibody-mediated targeting of cleavage-specific OPN-T cell interactions. <i>PLoS ONE</i> , 2019, 14, e0214938.	2.5	2
7	TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding. <i>JCI Insight</i> , 2019, 4, .	5.0	8
8	Anti-apoptotic activity of human matrix metalloproteinase-2 attenuates diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2018, 82, 88-99.	3.4	17
9	Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 991-1002.	3.8	16
10	Prochemerin cleavage by factor XIa links coagulation and inflammation. <i>Blood</i> , 2018, 131, 353-364.	1.4	31
11	Dynamic and tissue-specific proteolytic processing of chemerin in obese mice. <i>PLoS ONE</i> , 2018, 13, e0202780.	2.5	17
12	Chemerin 156F, generated by chymase cleavage of prochemerin, is elevated in joint fluids of arthritis patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 132.	3.5	20
13	Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1474-1486.	3.8	37
14	Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation Research</i> , 2017, 120, 1246-1262.	4.5	45
15	Chemerin activation in human obesity. <i>Obesity</i> , 2016, 24, 1522-1529.	3.0	67
16	Amelioration of Diabetes by Protein S. <i>Diabetes</i> , 2016, 65, 1940-1951.	0.6	25
17	Plasmin as a complement C5 convertase. <i>EBioMedicine</i> , 2016, 5, 20-21.	6.1	19
18	Prochemerin Cleavage By Factor XIa Links Adipogenesis, Inflammation and Coagulation. <i>Blood</i> , 2016, 128, 2561-2561.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1090-1102.	3.8	28
20	Evaluation of and recommendation for the nomenclature of the CPB2 gene product (also known as) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2015, 13, 2277-2278.	3.8	12
21	Thrombomodulin Modulates Dendritic Cells via Both Antagonism of High Mobility Group Protein B1 and an Independent Mechanism. <i>Allergy International</i> , 2014, 63, 57-66.	3.3	5
22	Thrombin Cleavage of Osteopontin Disrupts a Pro-chemotactic Sequence for Dendritic Cells, Which Is Compensated by the Release of Its Pro-chemotactic C-terminal Fragment. <i>Journal of Biological Chemistry</i> , 2014, 289, 27146-27158.	3.4	26
23	Carboxypeptidase B2 Is Protective in a Mouse Model of Shiga Toxin-Induced Hemolytic Uremic Syndrome. <i>Blood</i> , 2014, 124, 2804-2804.	1.4	29
24	Thrombin-activatable fibrinolysis inhibitor (TAFI) is enhanced in major trauma patients without infectious complications. <i>Immunobiology</i> , 2013, 218, 470-476.	1.9	18
25	Thrombin-Activatable Fibrinolysis Inhibitor Protects against Acute Lung Injury by Inhibiting the Complement System. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 646-653.	2.9	26
26	Thrombin-cleaved Fragments of Osteopontin Are Overexpressed in Malignant Glial Tumors and Provide a Molecular Niche with Survival Advantage. <i>Journal of Biological Chemistry</i> , 2013, 288, 3097-3111.	3.4	59
27	Dose-dependent differential effects of thrombin in allergic bronchial asthma. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1903-1915.	3.8	21
28	Differential Gene Expression in Thrombomodulin (TM; CD141)+ and TM ⁻ Dendritic Cell Subsets. <i>PLoS ONE</i> , 2013, 8, e72392.	2.5	11
29	Thrombomodulin Links Coagulation to Inflammation and Immunity. <i>Current Drug Targets</i> , 2012, 13, 421-431.	2.1	60
30	Role of Thrombin-Activatable Fibrinolysis Inhibitor in Allergic Bronchial Asthma. <i>Lung</i> , 2012, 190, 189-198.	3.3	16
31	Inhibition of Allergic Bronchial Asthma by Thrombomodulin Is Mediated by Dendritic Cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 31-42.	5.6	44
32	Proteolytic Cleavage of Chemerin Protein Is Necessary for Activation to the Active Form, Chem157S, Which Functions as a Signaling Molecule in Glioblastoma. <i>Journal of Biological Chemistry</i> , 2011, 286, 39510-39519.	3.4	52
33	Chemerin158K Protein Is the Dominant Chemerin Isoform in Synovial and Cerebrospinal Fluids but Not in Plasma. <i>Journal of Biological Chemistry</i> , 2011, 286, 39520-39527.	3.4	51
34	Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. <i>Journal of Clinical Investigation</i> , 2011, 121, 3517-27.	8.2	61
35	Chemerin Bioactivity Is Regulated by Factor XIa: A Novel Interface Linking Between Coagulation, Hemostasis and Immunity. <i>Blood</i> , 2011, 118, 2258-2258.	1.4	0
36	Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 808-816.	3.8	13

#	ARTICLE	IF	CITATIONS
37	What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 868-876.	3.8	61
38	High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2514-2522.	3.8	10
39	Enhanced Abdominal Aortic Aneurysm Formation in Thrombin-Activatable Procarboxypeptidase B-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1363-1370.	2.4	28
40	Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synovocyte binding in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2902-2912.	6.7	58
41	Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 139-146.	3.8	14
42	Structures of potent selective peptide mimetics bound to carboxypeptidase B. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2008, 64, 149-157.	2.5	16
43	Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. <i>Thrombosis and Haemostasis</i> , 2008, 100, 90-100.	3.4	15
44	A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - Part I: Pharmacological characterization. <i>Thrombosis and Haemostasis</i> , 2007, 97, 45-53.	3.4	27
45	A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. <i>Thrombosis and Haemostasis</i> , 2007, 97, 54-61.	3.4	45
46	Thrombin-Activatable Fibrinolysis Inhibitor Deficiency Attenuates Bleomycin-Induced Lung Fibrosis. <i>American Journal of Pathology</i> , 2006, 168, 1086-1096.	3.8	34
47	Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator of Vascular Inflammation. <i>Journal of Biological Chemistry</i> , 2003, 278, 51059-51067.	3.4	193
48	Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. <i>Thrombosis and Haemostasis</i> , 2003, 90, 414-421.	3.4	19
49	Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. <i>Journal of Clinical Investigation</i> , 2002, 109, 101-110.	8.2	105
50	Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. <i>Journal of Clinical Investigation</i> , 2002, 109, 101-110.	8.2	50
51	Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. <i>Nature</i> , 2000, 404, 518-525.	27.8	304
52	An Inhibitor of Activated Thrombin-Activatable Fibrinolysis Inhibitor Potentiates Tissue-Type Plasminogen Activator-Induced Thrombolysis in a Rabbit Jugular Vein Thrombolysis Model. <i>Thrombosis Research</i> , 2000, 98, 333-342.	1.7	127
53	Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activatable Fibrinolysis Inhibitor. <i>Journal of Biological Chemistry</i> , 1998, 273, 2792-2798.	3.4	106
54	TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex. <i>Journal of Biological Chemistry</i> , 1996, 271, 16603-16608.	3.4	557

#	ARTICLE	IF	CITATIONS
55	Recombinant soluble human thrombomodulin: A randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model. <i>Thrombosis Research</i> , 1994, 73, 385-394.	1.7	18
56	Structure-function studies of the epidermal growth factor domains of human thrombomodulin. <i>Biochemical and Biophysical Research Communications</i> , 1992, 185, 567-576.	2.1	34